January 8, 2026

The Honorable Martin A. Makary, M.D., M.P.H. Commissioner, U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993

The Honorable Robert F. Kennedy Jr. Secretary, U.S. Department of Health and Human Services 200 Independence Avenue, S.W. Washington, DC 20201

Dear Commissioner Makary and Secretary Kennedy,

As representatives of tens of thousands of pro-life obstetricians/gynecologists, pediatricians, family physicians, and other medical professionals dedicated to evidence-based care for women and their preborn children, we are deeply concerned to hear the news that the U.S. Food and Drug Administration (FDA) may be delaying its full review of the safety of mifepristone.

https://www.dailysignal.com/wp-content/uploads/2026/01/2026.01.08-Medical-Organizations-Letter.pdf

Respectfully,

Christina Francis, MD, dip ABOG CEO, American Association of Pro-Life OB/GYNs (AAPLOG)

Michelle K. Stanford, MD President, Catholic Medical Association (CMA)

Donna Harrison, MD Chair of the Board, Alliance for Hippocratic Medicine (AHM)

Mike Chupp, MD, FACS CEO, Christian Medical and Dental Association (CMDA)

Mike Artigues, MD, FCP President, American College of Pediatricians (ACPeds)